You are here : Home > News > A Ruthenium Nanocatalyst for Incorporating Hydrogen Isotopes into Medicines in Aqueous Media

Scientific result | Headlines | Europe | Chemistry | Pharmacology

A Ruthenium Nanocatalyst for Incorporating Hydrogen Isotopes into Medicines in Aqueous Media


​In collaboration with Sanofi and a Spanish laboratory, researchers from the SCBM have developed a ruthenium nanocatalyst that enables the efficient and precise incorporation of deuterium or tritium into complex polar molecules and biopharmaceuticals in aqueous media.

Published on 6 October 2026

In pharmaceutical research, the incorporation of tritium atoms (a radioactive isotope of hydrogen) into a drug candidate allows tracking its fate in the body: how it is distributed, absorbed, metabolized, and eliminated. This information is crucial before any market release. However, the nature of medicines is evolving. An increasing proportion of new active ingredients belongs to the family of biologics (or biopharmaceuticals), such as peptides, oligonucleotides, or antibody-drug conjugates, which combine an antibody with a small active molecule.

These molecules present a major challenge for chemists developing methods for incorporating deuterium and tritium. They are large, complex, fragile, and almost always soluble only in water, a medium poorly compatible with classical labeling methods. Therefore, it is necessary to design mild, highly selective methods that are tolerant to the presence of water.

Within the framework of the European project ISOBIOTICS, a team from the SCBM, in collaboration with a team from Sanofi (Frankfurt, Germany) and the CataNA laboratory (Seville, Spain), designed and characterized water-dispersible ruthenium nanoparticles stabilized by commercially available water-soluble ligands. These nanoparticles serve as catalysts for the reduction of carbonyl functions in aqueous media under low-pressure deuterium or tritium gas, a first of its kind. This approach thus enables the labeling of complex molecules such as peptides, cleavable links used in antibody-drug conjugates (ADCs), or polyethylene glycol derivatives, widely used in the design of biopharmaceuticals. For tritium labeling, the method is particularly promising: it is highly selective and requires only small amounts of radioactive gas to achieve strong incorporation.

Overall, these results, published in the journal Angewandte Chemie as a "VIP paper," highlight the broad potential of the method for the isotopic labeling of hydrogen in complex polar molecules and biopharmaceuticals.

Contact at the Frédéric-Joliot Institute for Life sciences:

Grégory P​​​ieters (gregory.pieters@cea.fr) ​

European fundings
This work ​was carried out as part of the DOCTORAL NETWORKS ISOBIOTICs program, coordinated by Grégory Pieters​


​​​
​

Top page

Top page